- Home
- MOLN vs INZY Comparison
MOLN vs INZY Comparison
Compare MOLN & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- INZY
- Stock Information
- Founded
- MOLN 2004
- INZY 2015
- Country
- MOLN Switzerland
- INZY United States
- Employees
- MOLN N/A
- INZY N/A
- Industry
- MOLN
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- INZY Health Care
- Exchange
- MOLN Nasdaq
- INZY Nasdaq
- Market Cap
- MOLN 136.1M
- INZY 256.3M
- IPO Year
- MOLN 2021
- INZY 2020
- Fundamental
- Price
- MOLN $3.72
- INZY N/A
- Analyst Decision
- MOLN
- INZY Buy
- Analyst Count
- MOLN 0
- INZY 9
- Target Price
- MOLN N/A
- INZY $15.22
- AVG Volume (30 Days)
- MOLN 1.8K
- INZY 989.2K
- Earning Date
- MOLN 08-25-2025
- INZY 08-05-2025
- Dividend Yield
- MOLN N/A
- INZY N/A
- EPS Growth
- MOLN N/A
- INZY N/A
- EPS
- MOLN N/A
- INZY N/A
- Revenue
- MOLN $2,525,030.00
- INZY N/A
- Revenue This Year
- MOLN N/A
- INZY N/A
- Revenue Next Year
- MOLN $866.67
- INZY N/A
- P/E Ratio
- MOLN N/A
- INZY N/A
- Revenue Growth
- MOLN N/A
- INZY N/A
- 52 Week Low
- MOLN $3.36
- INZY $0.72
- 52 Week High
- MOLN $12.22
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- MOLN 49.47
- INZY 82.67
- Support Level
- MOLN $3.71
- INZY $3.94
- Resistance Level
- MOLN $3.89
- INZY $3.97
- Average True Range (ATR)
- MOLN 0.15
- INZY 0.01
- MACD
- MOLN 0.01
- INZY -0.08
- Stochastic Oscillator
- MOLN 41.27
- INZY 100.00
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.